Yellox
bromfenac
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Yellox. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Yellox.
For practical information about using Yellox, patients should read the package leaflet or contact their doctor or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Yellox
|
Agency product number |
EMEA/H/C/001198
|
Active substance |
bromfenac sodium sesquihydrate
|
International non-proprietary name (INN) or common name |
bromfenac
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
S01BC11
|
Publication details | |
---|---|
Marketing-authorisation holder |
Bausch + Lomb Ireland Limited
|
Revision |
11
|
Date of issue of marketing authorisation valid throughout the European Union |
18/05/2011
|
Contact address |
3013 Lake Drive |
Product information
04/02/2022 Yellox - EMEA/H/C/001198 - T/0031
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Ophthalmologicals
Therapeutic indication
Treatment of postoperative ocular inflammation following cataract extraction in adults.